Telomir Pharmaceuticals TELO 深 沪
等待开盘 10-03 09:30:00 美东时间
1.39
0.000
0.00%
华盛通- 最 高1.40
- 今 开1.40
- 成交量 18.54万股
- 最 低 1.36
- 昨 收 1.39
- 总市值 4137.02万
- 52周最高 7.0791
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 1.12
- 委 比 66.94%
- 总股本 2976.27万
- 历史最高 20.72
- 量 比 0.52
- 振 幅 2.88%
- 历史最低 1.12
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tesla Co-Founder Takes On Elon Musk, Jeff Bezos With Plans For $41,000 Electric Truck
A Tesla co-founder is back in the electric vehicle space and will be taking his former company head on with plans for an electric pickup truck on market in 2026.
09-25 07:09
Telomir Pharmaceuticals’ Telomir-1 Shows Broad-Spectrum Efficacy
Telomir Pharmaceuticals, Inc. ( ($TELO) ) has shared an update. Telomir Pharmac...
09-18 19:56
Telomir Pharma Study Shows Telomir-1 Blocks Cancer-Linked Gene Regulators In Lab Tests
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) today announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family. Histone demethylases are
09-18 19:35
Telomir Pharmaceuticals Reported New Preclinical Cancer Data In Aggressive Human Prostate Cancer Cell Models Showing That Telomir-1 Inhibited DNA Hypermethylation Of CDKN2A, A Master Tumor Suppressor Gene-8K Filing
CDKN2A plays a central role in controlling uninhibited cell growth and initiating programmed cell death, and its silencing is a well-established hallmark of cancer progression.Telomir-1 outperformed both Rapamycin and
09-09 19:49
Market-Moving News for August 28th
TELO: 61% | Telomir Pharmaceuticals shares are trading higher after the company reported results for Telomir-1. SNOW: 14% | Snowflake shares are trading higher after the company reported Q2 financial
08-28 19:17
Telomir Pharmaceuticals Inc Reports Telomir-1 Potently Inhibits UTX, A Key Histone Demethylase Involved In Regulating Gene Expression Through DNA Methylation
- SEC Filing Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root mechanisms of cancer, aging, and age-related diseases, today announced
08-28 04:13
Watching Telomir Pharmaceuticals; Zacks Small-Cap Research Gives Stock $15.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08152025_TELO_Sorensen.pdf
08-16 00:26
Telomir Pharmaceuticals Q2 EPS $(0.17) Misses $(0.08) Estimate
Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.08) by 112.5 percent. This is a 240 percent decrease over losses of $(0.05) per
08-15 04:18
Telomir Pharmaceuticals Unveils Promising In Vitro Data
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). ...
08-07 20:29
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 151.2% to $3.04 duri...
07-18 20:07
